MoH approved the use of Tocilizumab or Sarilumab drugs to treat severe COVID patients

MoH approved the use of Tocilizumab or Sarilumab drugs to treat severe COVID patients

As of 7th July, 2021, the Ministry of Health has approved the use of IL-6 receptor blockers, (Tocilizumab or Sarilumab) as a therapeutic in the treatment of patients with severe or critical COVID-19.

This decision to approve these therapeutics in Trinidad and Tobago is based on the findings and recommendations of the “World Health Organization Therapeutics and COVID19 Living Guidelines” report of 6th July, 2021.

The WHO has further recommended that patients with severe and critical COVID-19 should now receive both corticosteroids and IL-6 receptor blockers. These drugs are currently available in Trinidad and Tobago.

Clinical leads throughout the Regional Health Authorities (RHAs) were notified and have received authorization to immediately commence use of these drugs on patients with severe or critical COVID-19, when required.

The Ministry further advises the public that the following drugs have not received WHO approval for use and are therefore, not authorized in the treatment of COVID-19 positive patients in the public health system at this time:

 Remdesivir
 Lopinavir/Ritonavir
 Hydroxychloroquine
 Ivermectin

COMMENTS

WORDPRESS: 0
DISQUS: 0